OpGen, Inc.

Equities

OPGN

US68373L5057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
3.06 ^USD	-10.26%		-7.27%	-27.14%

04-24	OpGen Gets Notice of Noncompliance From Nasdaq	MT
03-26	Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	MT

OpGen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021

January 10, 2022 at 04:32 pm

OpGen, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year 2021. Preliminary revenue for the fourth quarter of 2021 was approximately $1.4 million compared to approximately $1.4 million in the fourth quarter of 2020.

Total preliminary unaudited revenue for OpGen in 2021 was approximately $4.3 million, compared to approximately $4.2 million in 2020.

Latest news about OpGen, Inc.

OpGen Gets Notice of Noncompliance From Nasdaq	04-24	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	03-26	MT
OpGen, Inc. Announces Management Changes	03-25	CI
OpGen, Inc. Announces Chief Executive Officer Changes	03-25	CI
OpGen, Inc. announced that it expects to receive $3 million in funding	03-24	CI
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022	11-14	MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
OpGen to Raise $1 Million From Private Placement Amid Talks For 'Potential Strategic' Deal	23-10-12	MT
OpGen, Inc. announced that it expects to receive $1 million in funding	23-10-10	CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT
Investors Await Inflation Data, Consumer Sentiment Report as US Futures Trend Higher Friday	23-09-29	MT
Top Premarket Gainers	23-09-29	MT
North American Morning Briefing : China Angst -2-	23-08-15	DJ
HC Wainwright Downgrades OpGen to Neutral From Buy	23-08-14	MT
Opgen Exploring Options	23-08-10	CI
OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : OpGen, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (OPGN) OPGEN Reports Q2 Revenue $736,136, vs. Street Est of $900,000	23-08-10	MT
Transcript : OpGen, Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
Earnings Flash (OPGN) OPGEN Posts Q1 Revenue $0.91M	23-05-15	MT
OpGen, Inc. Provides Revenue Guidance for the Year 2023	23-05-15	CI
OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
US Stocks Set to Open Lower Amid Earnings Reports, Rising Personal Income	23-04-28	MT
OpGen, Fisher Healthcare Sign Non-Exclusive Distribution Agreement for Unyvero A50 Platform	23-04-18	MT
Opgen, Inc. Submits De Novo Request to the U.S. FDA for Unyvero Urinary Tract Infection Panel	23-04-18	CI

Chart OpGen, Inc.

Duration

Period

More charts

Company Profile

OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
OPGEN, INC.	-27.14%	3.86M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research

OpGen, Inc.

Equities

OPGN

US68373L5057

Biotechnology & Medical Research

OpGen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021

Latest news about OpGen, Inc.

Chart OpGen, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research